Literature DB >> 16282416

Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.

Mark Sheehan.   

Abstract

Mesh：

Year:  2005        PMID： 16282416      PMCID： PMC1283316          DOI： 10.1136/bmj.331.7525.1144-c

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

Review 1.  Orphan drugs and the NHS: should we value rarity?

Authors:  Christopher McCabe; Karl Claxton; Aki Tsuchiya
Journal:  BMJ       Date:  2005-10-29
  1 in total
  3 in total

Review 1.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

2.  Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.

Authors:  Katarzyna Kolasa; Krzysztof M Zwolinski; Zoltan Kalo; Tomasz Hermanowski
Journal:  Orphanet J Rare Dis       Date:  2016-03-10       Impact factor: 4.123

Review 3.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.